The document cannot be parsed.
6 citations
,
April 1996 in “Journal of histochemistry and cytochemistry/The journal of histochemistry and cytochemistry” TGF-alpha is present in sheep and ferret skin and may affect hair growth without directly stimulating cell proliferation.
32 citations
,
July 2017 in “Wiley Interdisciplinary Reviews-Developmental Biology” Transit-amplifying cells are crucial for tissue repair and can contribute to cancer when they malfunction.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
July 2008 in “International journal of psychophysiology” Cyproterone acetate is a safe treatment that causes mild feminizing effects in adolescent trans-girls.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
May 2023 in “Zenodo (CERN European Organization for Nuclear Research)”
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
October 2020 in “Journal of Pharmaceutical Sciences” Topical finasteride with EGCG or TA improves drug release and dermal uptake, potentially treating hair loss effectively.
July 2025 in “Journal of Investigative Dermatology” Enhancing Tregs can protect against alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Tissue-engineered skin substitutes can model junctional epidermolysis bullosa and may help develop gene therapy.
April 2019 in “Journal of Investigative Dermatology” Frontal Fibrosing Alopecia involves disrupted cholesterol pathways, fibrosis, and increased mast cells.
45 citations
,
March 1997 in “Journal of Investigative Dermatology”
April 2024 in “Current Rheumatology Reviews” MCTD should be considered in children with recurring muscle issues, lupus-like symptoms, and edema.
January 2026 in “Biomolecules” TSC22D genes are key in metabolic diseases and cancer, offering potential as treatment targets.
3 citations
,
August 2017 in “Clinical case reports” A rare skin condition causes red and dark patches on the face and limbs.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
1 citations
,
February 2025 in “Pediatric Dermatology” Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
69 citations
,
January 2013 in “Frontiers in Immunology” The FOXN1 gene is crucial for developing immune cells and preventing immune disorders.
36 citations
,
February 1998 in “Journal of Anatomy” Fibre optic confocal imaging can visualize skin layers, blood vessels, and nerves in live mice.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
2 citations
,
January 2025 in “Dilemas contemporáneos Educación Política y Valores” Better physical condition leads to improved quality of life in older adults.
GV-350 improves hair growth and quality of life in iron-deficient women without side effects.
June 2023 in “Benha Journal of Applied Sciences” People with chronic hair shedding have lower antioxidant levels in their blood compared to healthy individuals.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
88 citations
,
August 2019 in “Nature communications” Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
53 citations
,
August 2019 in “American journal of human genetics” FOXN1 gene variants cause low T cells and immune issues from birth.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
415 citations
,
January 2008 in “Cell” NFATc1 controls hair stem cell activity, affecting hair growth and could be a target for hair loss treatments.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.